Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i

Susanne Singer; Juan I. Arraras; Ingo Baumann; Andreas Boehm; Wei Chu Chie; Razvan Galalae; Johannes A. Langendijk; Orlando Guntinas-Lichius; Eva Hammerlid; Monica Pinto; Ourania Nicolatou-Galitis; Claudia Schmalz; Mehmet Sen; Allen C. Sherman; Karin Spiegel; Irma Verdonck-De Leeuw; Noam Yarom; Paola Zotti; Dirk Hofmeister

doi:10.1002/hed.23127

Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i

Susanne Singer^*, Juan I. Arraras, Ingo Baumann, Andreas Boehm, Wei Chu Chie, Razvan Galalae, Johannes A. Langendijk, Orlando Guntinas-Lichius, Eva Hammerlid, Monica Pinto, Ourania Nicolatou-Galitis, Claudia Schmalz, Mehmet Sen, Allen C. Sherman, Karin Spiegel, Irma Verdonck-De Leeuw, Noam Yarom, Paola Zotti, Dirk Hofmeister

^*Corresponding author for this work

School of Dentistry

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Background The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. Methods The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. Results Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. Conclusions Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.

Original language	English
Pages (from-to)	1331-1338
Number of pages	8
Journal	Head and Neck
Volume	35
Issue number	9
DOIs	https://doi.org/10.1002/hed.23127
State	Published - Sep 2013

Keywords

chemoradiation
head and neck neoplasms
larynx
multimodal therapies
oral cavity
pharynx

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.23127

Cite this

Singer, S., Arraras, J. I., Baumann, I., Boehm, A., Chie, W. C., Galalae, R., Langendijk, J. A., Guntinas-Lichius, O., Hammerlid, E., Pinto, M., Nicolatou-Galitis, O., Schmalz, C., Sen, M., Sherman, A. C., Spiegel, K., Verdonck-De Leeuw, I., Yarom, N., Zotti, P., & Hofmeister, D. (2013). Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i. Head and Neck, 35(9), 1331-1338. https://doi.org/10.1002/hed.23127

@article{9c8f37f396cd42cab00892286a4f8e3b,

title = "Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i",

abstract = "Background The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. Methods The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. Results Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. Conclusions Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.",

keywords = "chemoradiation, head and neck neoplasms, larynx, multimodal therapies, oral cavity, pharynx",

author = "Susanne Singer and Arraras, {Juan I.} and Ingo Baumann and Andreas Boehm and Chie, {Wei Chu} and Razvan Galalae and Langendijk, {Johannes A.} and Orlando Guntinas-Lichius and Eva Hammerlid and Monica Pinto and Ourania Nicolatou-Galitis and Claudia Schmalz and Mehmet Sen and Sherman, {Allen C.} and Karin Spiegel and {Verdonck-De Leeuw}, Irma and Noam Yarom and Paola Zotti and Dirk Hofmeister",

year = "2013",

month = sep,

doi = "10.1002/hed.23127",

language = "אנגלית",

volume = "35",

pages = "1331--1338",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "9",

}

Singer, S, Arraras, JI, Baumann, I, Boehm, A, Chie, WC, Galalae, R, Langendijk, JA, Guntinas-Lichius, O, Hammerlid, E, Pinto, M, Nicolatou-Galitis, O, Schmalz, C, Sen, M, Sherman, AC, Spiegel, K, Verdonck-De Leeuw, I, Yarom, N, Zotti, P & Hofmeister, D 2013, 'Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i', Head and Neck, vol. 35, no. 9, pp. 1331-1338. https://doi.org/10.1002/hed.23127

TY - JOUR

T1 - Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i

AU - Singer, Susanne

AU - Arraras, Juan I.

AU - Baumann, Ingo

AU - Boehm, Andreas

AU - Chie, Wei Chu

AU - Galalae, Razvan

AU - Langendijk, Johannes A.

AU - Guntinas-Lichius, Orlando

AU - Hammerlid, Eva

AU - Pinto, Monica

AU - Nicolatou-Galitis, Ourania

AU - Schmalz, Claudia

AU - Sen, Mehmet

AU - Sherman, Allen C.

AU - Spiegel, Karin

AU - Verdonck-De Leeuw, Irma

AU - Yarom, Noam

AU - Zotti, Paola

AU - Hofmeister, Dirk

PY - 2013/9

Y1 - 2013/9

N2 - Background The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. Methods The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. Results Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. Conclusions Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.

AB - Background The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. Methods The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. Results Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. Conclusions Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.

KW - chemoradiation

KW - head and neck neoplasms

KW - larynx

KW - multimodal therapies

KW - oral cavity

KW - pharynx

UR - http://www.scopus.com/inward/record.url?scp=84883051141&partnerID=8YFLogxK

U2 - 10.1002/hed.23127

DO - 10.1002/hed.23127

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 22907791

AN - SCOPUS:84883051141

SN - 1043-3074

VL - 35

SP - 1331

EP - 1338

JO - Head and Neck

JF - Head and Neck

IS - 9

ER -

Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this